Risk-Based Therapeutic StrategiesCorre, Jill, PharmD, PhD; Avet-Loiseau, Hervé, MD, PhDThe Cancer Journal: January/February 2019 - Volume 25 - Issue 1 - p 54–58 doi: 10.1097/PPO.0000000000000352 Review Articles Buy SDC Abstract Author InformationAuthors Article MetricsMetrics Although therapeutic strategies have been adapted to age and comorbidities of myeloma patients for a long time, all patients currently experiment the same treatment whatever their genomic risk. However, high-risk patients should benefit right now from the most efficient drugs combinations. Herein, we review and discuss how to optimally define risk to adapt treatment and why a modern multiparametric definition of genomic risk is urgently needed. Minimal residual disease status will probably also take a growing place in patient's management, including in treatment adaptation. We also discuss how next-generation sequencing will definitively represent an essential tool to manage risk-based therapeutic strategies. Finally, despite an explosive knowledge of myeloma molecular landscape, targeted therapy perspectives remain poor, with only few exceptions. From the IUC-Oncopole and CRCT INSERM U1037, Toulouse, France. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article. Reprints: Jill Corre, PharmD, PhD, Unit for Genomics in Myeloma, Institut Universitaire du Cancer, avenue Irene Joliot-Curie, 31059 Toulouse, France. E-mail: firstname.lastname@example.org. Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.